Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227922 · ClinicalTrials.gov registry record · Phase 1
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
A Phase 1 study of Moderate Renal Impairment, sponsored by Sparrow Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT07227922 is a Phase 1 study of Moderate Renal Impairment that is actively recruiting participants, run by Sparrow Pharmaceuticals. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07227922, a Phase 1 study of Moderate Renal Impairment, is actively recruiting participants, sponsored by Sparrow Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Conditions Studied
Interventions
- DRUG 12mg clofutriben
Study Locations (1)
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-11-30 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227922
The ClinicalTrials.gov registry entry for NCT07227922 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sparrow Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which 12mg clofutriben is the first listed.
NCT07227922 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07227922 about?
NCT07227922 is a clinical study titled "Clofutriben Pharmacokinetics in Patients With Impaired Renal Function". This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
What is the current status of trial NCT07227922?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-11-30. Estimated completion is 2026-07-01.
What conditions does trial NCT07227922 study?
This clinical trial studies the following conditions: Moderate Renal Impairment.
What interventions are being tested in trial NCT07227922?
The interventions under investigation include: 12mg clofutriben (DRUG).
Who is sponsoring clinical trial NCT07227922?
This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227922 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.